Nano Dimension Ltd. filings document results of operations, ADS-related governance, portfolio actions, and public-company reporting matters for an Israel-incorporated digital manufacturing issuer listed on Nasdaq. Recent Form 8-K reports furnish financial results, product-line monetization announcements, strategic alternatives disclosures, and updates tied to the company's manufacturing technology portfolio.
The filing record also includes a Form 12b-25 notice related to the timing of the company's Form 10-K and disclosures about internal control over financial reporting, as well as an 8-K describing a limited-duration shareholder rights agreement for ADS holders. Earlier foreign-issuer materials on Form 6-K include shareholder communications and proxy-related materials.
Nano Dimension Ltd. reported that Chief Executive Officer David Stehlin had 24,971 ordinary shares withheld on July 13, 2026 at $1.4800 per share. The issuer retained these shares to satisfy tax withholding obligations associated with the vesting of restricted stock units. Following this tax-withholding disposition, Stehlin directly holds 737,032 ordinary shares.
David Stehlin has notified of a proposed sale of up to 24,971 Nano Dimension Ltd. American Depositary Shares representing Ordinary Shares through Oppenheimer & Co. Inc. on or about July 13, 2026, to be traded on Nasdaq. The securities were issued upon vesting of restricted stock units, with 578,703 shares issued at no cash consideration. Over the prior three months, he sold 18,276, 19,832, and 19,841 ADSs on April 27, May 11, and June 9, 2026, for aggregate prices of $33,108.80, $31,735.17, and $30,207.92, respectively.
Tang Capital Management and related entities filed a Schedule 13D on Nano Dimension Ltd., disclosing beneficial ownership of 14,292,813 Ordinary Shares, equal to 6.8% of the company. These shares are held as American Depository Shares, each representing one Ordinary Share.
The filing states that approximately $19.5 million of working capital from various Tang Capital funds was used to acquire the position. On June 30, 2026, Tang Capital Management sent Nano Dimension a merger proposal involving an affiliate of the reporting group. The proposal is non-binding and subject to limited confirmatory diligence and negotiation of a definitive merger agreement, and there is no assurance discussions will occur or lead to a transaction.
Murchinson Ltd. and affiliated investors filed Amendment No. 17 to their Schedule 13D on Nano Dimension Ltd., updating their ownership and group arrangements. The filing shows aggregate beneficial ownership of 20,285,450 American Depositary Shares by Murchinson and 20,285,450 ADS by Marc J. Bistricer, each representing 9.6% of the 210,354,507 Shares outstanding as of May 27, 2026. Nomis Bay Ltd. reports 6,093,483 Shares (2.9%), BPY Ltd. reports 4,049,242 Shares (1.9%), and EOM Management Ltd. reports 10,142,725 Shares (4.8%), largely through managed positions. The amendment details that these positions were bought with working capital, provides approximate aggregate purchase prices and ADS conversion fees, and formalizes a Joint Filing Agreement among nine reporting persons.
Nano Dimension Ltd. is the target of a shareholder solicitation by Murchinson Ltd., which says it beneficially owns 16,285,450 ADSs (each representing one Ordinary Share), or approximately 7.7% of the outstanding Shares, and has demanded an extraordinary general meeting to seek approval of six proposals including declassification of the board, limits on rights plans and major transactions, removal of three directors, and appointment of three nominees.
Murchinson recommends voting “FOR” Proposals No. 2–6 and provides a [COLOR] proxy card; record dates, meeting date and certain procedural dates are left blank in the furnished excerpt.
Oramed Pharmaceuticals Inc. filed Amendment No. 2 to its Schedule 13D on Nano Dimension Ltd., updating its ownership and recent trading activity. Oramed reports beneficial ownership of 15,079,708 Ordinary Shares, representing 7.2% of Nano Dimension’s Ordinary Shares outstanding as of May 27, 2026.
Between May 13 and June 15, 2026, Oramed spent about $8.7 million buying an additional 6,336,565 Ordinary Shares in open-market transactions and entered into significant call and put option positions referencing millions of shares. Oramed states it has sole voting and dispositive power over its position.
Oramed also discloses that it is strongly opposed to Nano Dimension’s recently announced term sheet with Infinite Epigenetics to form an AI-powered preventive health and diagnostics company, and is evaluating its options regarding this proposed transaction.
Nano Dimension Ltd. issued a press release on June 16, 2026 providing additional information about its proposed business combination with Infinite Epigenetics, Inc. The company has filed a preliminary proxy statement and intends to file a definitive proxy statement and a Form S-4 registration statement if a definitive agreement is executed. The filings will seek shareholder approval at an Extraordinary General Meeting that will include a non-binding advisory proposal on continuation of Nano's strategic alternatives review process. The company names its President and CEO, David Stehlin, and its non-employee directors as participants in the solicitation and furnishes a press release as Exhibit 99.1.
Nano Dimension used this update to defend and explain its proposed business combination with Infinite Epigenetics, which would pivot the business from 3D printing toward AI-powered preventive health and diagnostics. Infinite operates a CLIA-certified methylation lab, has a network of more than 7,500 healthcare providers, over 50 peer‑reviewed publications and a proprietary database of more than 120,000 biological samples. Nano emphasizes the chronic disease diagnostics market exceeds $90 billion and says Infinite’s model blends diagnostic testing with a biological AI platform built on proprietary data. The company states the contemplated transaction values Nano at net cash plus a 20% premium, with Nano shareholders retaining contingent value rights on legacy assets and receiving two seats on the combined company’s board. Management argues this offers better long-term value than liquidating and returning cash, and contrasts its detailed plan with activist Murchinson’s push to replace a majority of the board. Any definitive agreement would later be filed on Form S-4 and put to a shareholder vote.
Nano Dimension Ltd. entered a non-binding term sheet with Infinite Epigenetics on June 15, 2026 to pursue a business combination under which Nano (or a successor public company) would acquire all issued and outstanding equity interests of Infinite in exchange for Nano ordinary shares or ADSs.
The Term Sheet values Infinite at $890 million (less a defined Premium) and sets Nano's post-transaction ownership math using Nano's Net Cash plus a 20% premium and an agreed valuation for Essemtec (estimated at $20 million). The Term Sheet contemplates a seven-member board with Infinite initially designating four directors (five if Infinite holders exceed 55% on a fully diluted basis), a 30-day exclusivity period, and potential reimbursement of Infinite's documented out-of-pocket deal costs up to $3 million if a definitive agreement is not executed before Nano's next extraordinary general meeting.